Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
- PMID: 18952677
- DOI: 10.1093/brain/awn235
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
Abstract
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease patients and represents a major limitation for the pharmacological management of the motor symptoms in advanced disease stages. We have recently demonstrated that dopamine released from serotonin neurons is responsible for l-DOPA-induced dyskinesia in 6-hydroxydopamine (6-OHDA)-lesioned rats, raising the possibility that blockade of serotonin neuron activity by combination of 5-HT(1A) and 5-HT(1B) agonists could reduce l-DOPA-induced dyskinesia. In the present study, we have investigated the efficacy of 5-HT(1A) and 5-HT(1B) agonists to counteract l-DOPA-induced dyskinesia in 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (MPTP)-treated macaques, the gold standard model of Parkinson's disease. In addition, we have studied the ability of this treatment to prevent development of l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. The results demonstrate the existence of a potent synergistic effect between 5-HT(1A) and 5-HT(1B) agonists in their ability to dampen l-DOPA-induced dyskinesia in the MPTP-treated macaques. Sub-threshold doses of the drugs, which individually produced no effect, were able to reduce the abnormal involuntary movements by up to 80% when administered in combination, without affecting the anti-parkinsonian properties of l-DOPA. Furthermore, chronic administration of low doses of the 5-HT(1) agonists in combination was able to prevent development of dyskinesia, and reduce the up-regulation of FosB after daily treatment with l-DOPA in the rat 6-OHDA model. Our results support the importance of a clinical investigation of the effect of 5-HT(1A) and 5-HT(1B) agonists, particularly in combination, in dyskinetic l-DOPA-treated Parkinson's disease patients.
Similar articles
-
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.Neurobiol Aging. 2010 Jun;31(6):926-36. doi: 10.1016/j.neurobiolaging.2008.06.017. Epub 2008 Aug 15. Neurobiol Aging. 2010. PMID: 18707801
-
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.Brain. 2007 Jul;130(Pt 7):1819-33. doi: 10.1093/brain/awm082. Epub 2007 Apr 23. Brain. 2007. PMID: 17452372
-
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.Parkinsonism Relat Disord. 2009 Jul;15(6):445-52. doi: 10.1016/j.parkreldis.2008.11.001. Epub 2009 Feb 3. Parkinsonism Relat Disord. 2009. PMID: 19196540
-
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Prog Brain Res. 2008. PMID: 18772047 Review.
-
Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.Mov Disord. 2008;23 Suppl 3:S585-98. doi: 10.1002/mds.22022. Mov Disord. 2008. PMID: 18781676 Review.
Cited by
-
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.J Neural Transm (Vienna). 2011 Dec;118(12):1661-90. doi: 10.1007/s00702-011-0698-2. Epub 2011 Sep 1. J Neural Transm (Vienna). 2011. PMID: 21881839 Review.
-
Fluoxetine improves the effect of levodopa on 6-hydroxy dopamine-induced motor impairments in rats.Adv Pharm Bull. 2012;2(2):149-55. doi: 10.5681/apb.2012.023. Epub 2012 Jun 15. Adv Pharm Bull. 2012. PMID: 24312786 Free PMC article.
-
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets.Neuropharmacology. 2020 May 1;167:107997. doi: 10.1016/j.neuropharm.2020.107997. Epub 2020 Feb 10. Neuropharmacology. 2020. PMID: 32057799 Free PMC article.
-
Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease.Front Pharmacol. 2020 Dec 15;11:595635. doi: 10.3389/fphar.2020.595635. eCollection 2020. Front Pharmacol. 2020. PMID: 33384602 Free PMC article. Review.
-
The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.J Neural Transm (Vienna). 2018 Aug;125(8):1195-1202. doi: 10.1007/s00702-018-1865-5. Epub 2018 Feb 26. J Neural Transm (Vienna). 2018. PMID: 29480391 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous